Keywords: fibrogen, fg-4539, reduces, brain, tissue, damage, ischemic
FibroGen's FG-4539 reduces brain tissue damage in ischemic stroke
Article | 27 February 2006
Florida, USA-based FibroGen has said that a single dose of FG-4539, its novel small-molecule inhibitor of hypoxia-inducible factor (HIF) prolyl ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
